Tirzepatide treatment results in successful weight loss regardless of obesity-related complications

FHS
June 3, 2024
4:18 pm

Having medical conditions linked to obesity does not impact the total weight loss achieved with the anti-obesity medication tirzepatide, according to an industry-supported study being presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.

California lawmakers preserve aid to older, disabled immigrants

California lawmakers on Thursday passed a 2024-25 budget that rejected Gov. Gavin Newsom’s proposal to cut in-home supportive services for low-income older, blind, and disabled

June 14, 2024

Myelofibrosis: Beyond Ruxolitinib

Up until fairly recently, ruxolitinib (Jakafi) was the only FDA-approved treatment for intermediate- and high-risk myelofibrosis, and thus has been the cornerstone of myelofibrosis treatment

June 8, 2024

Novo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like Ozempic

WASHINGTON – Novo Nordisk spent $11 million on meals and travel for thousands of doctors last year, federal records show, as part of its push

July 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.